Analysis Of Full-length Transcripts For Variant Classification In Breast Cancer
Problem:
Genetic screening for breast cancer in New Zealand needs better tests to accurately identify high-risk genes and manage families at risk.
Project:
This study focuses on less-known high-risk breast cancer genes using new nanopore sequencing technology. This method will help identify mutations more reliably in genes like CDH1, PALB2 and others.
Outcome:
With more accurate results, doctors can offer better surveillance, treatments, and surgeries to reduce the risk of developing breast cancer.
Future:
The research findings will help create global guidelines and improve testing for all, including better understanding of cancer risks for New Zealand populations.
Project Update:
This project, done with experts locally and globally, improved technology and guidelines for identifying changes to important breast cancer genes like BRCA1/2 and others. These new guidelines are now used worldwide and approved by the US FDA. With a $1.19M grant, Logan and his team will study how these findings help in clinics to support healthcare that is improved and equitable across New Zealand populations.
Keep reading
View all
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Problem:Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can fa...
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Problem:Traditional pathology uses microscopes to examine tissue slides, but this method can be slow and inconsistent, and not all patients can afford advanced molecular testing. Project:Digital pa...
“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
ProblemTriple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, a...
